In Albanian In Bulgarian In Macedonian In Romanian In Serbian
Amgen, a leading international company in the biotechnology sector, has announced that Dr. Alina Kulcea will expand her functions as CEO in Romania, taking over the management of the Bulgarian division as well, BalkanEngineer.com has learned from Progressive.bg. The announcement of this key change in the company's management has already generated considerable interest in the business community.
Dr. Kulcea is a medical professional, a graduate of the Karol Davila University in Bucharest, and has an impressive track record in the pharmaceutical industry with over 25 years of experience. Prior to joining Amgen, she held important positions at Novartis Romania, where she established herself as a high-impact executive in the field of institutional relations.
In 2018, Dr. Kulcea moved to Amgen Romania, where she quickly built her reputation as an effective leader who not only drove the development of the company's Romanian division, but also improved market access and established the company's ethical standards. Her new role includes managing the operations of Amgen Bulgaria, where she will succeed Dr. Krassimira Chemisanska.
Dr Kulcea said she accepted this challenge with great responsibility and honour and expressed her gratitude to Dr Chemisanska for her previous work and dedication. She stressed the need for innovation and collaboration, especially in light of the global challenges the world is currently facing, such as the effects of the COVID-19 pandemic and geopolitical tensions.
Dr. Kulcea is expected to continue to promote the development of Amgen in the region by focusing on innovation and continuous process improvement in the important field of biotechnology and pharmaceuticals. It is expected that under her leadership, the company will continue to be a leading player in the sector and continue to meet the needs of patients by providing them with innovative and effective biological therapies.
Photo source: Amgen